Invus Public Equities, L.P. 13D and 13G filings for Syros Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-12 4:30 pm Sale |
2024-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS |
Invus Public Equities, L.P. | 1,063,829 3.800% |
-2,587,372 (-70.86%) |
Filing |
| 2024-11-12 4:30 pm Purchase |
2024-09-30 | 13G | Syros Pharmaceuticals, Inc. SYRS |
Invus Public Equities, L.P. | 3,651,201 9.900% |
82,359 (+2.31%) |
Filing |
| 2024-08-02 6:39 pm Purchase |
2024-07-25 | 13G | Syros Pharmaceuticals, Inc. SYRS |
Invus Public Equities, L.P. | 3,568,842 9.900% |
3,568,842 (New Position) |
Filing |